Ion; 2011.doi:10.11861475-2875-12-450 Cite this article as: Quashie et
Ion; 2011.doi:ten.11861475-2875-12-450 Cite this short article as: Quashie et al.: A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum H2 Receptor Accession clinical isolates to a panel of anti-malarial drugs. Malaria Journal 2013 12:450.KDM4 medchemexpress Submit your next manuscript to BioMed Central and take complete benefit of:Convenient on the web submission Thorough peer assessment No space constraints or color figure charges Quick publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which can be freely out there for redistributionSubmit your manuscript at biomedcentralsubmit
HIPPOKRATIA 2013, 17, 2:187-CASE REPORTBleomycin cardiotoxicity through chemotherapy for an ovarian germ cell tumorDidagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C1st Department of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, Thessaloniki, GreeceAbstract Introduction: Platinum-based chemotherapeutic regimens, including BEP (bleomycin, etoposide, cisplatin) represent the regular of care, initial line therapy in non-epithelial ovarian tumours. Cardiovascular toxicity is often a rare adverse impact of bleomycin. Case Report: A 41-year-old woman with ovarian granulosa tumor, treated with very first line BEP chemotherapy knowledgeable chest discomfort swiftly progressing to severe precordial discomfort in the course of bleomycin infusion. The infusion was stopped and electrocardiographic adjustments indicative of myocardial ischemia were revealed. Anti-anginal and anti-thrombotic remedy was introduced. Cardiac enzymes weren’t elevated and echocardiographic findings showed no wall motion abnormalities. Twenty 4 hours following the episode the elctrocardiographic adjustments insisted and chemotherapy was decided to become continued, excluding bleomycin, with no symptom recurrence. Discussion: Cardiovascular complications pose a uncommon but possible fatal adverse effect of BEP chemotherapy and needs to be cautiously addressed, particularly in individuals with more cardiovascular risk elements. Physicians coping with bleomycin-based therapies may find this understanding helpful to get a much more extensive evaluation of chest pain syndromes in these individuals. Hippokratia 2013, 17, 2: 1787-188 Key phrases: BEP chemotherapy, ovarian cancer, cardiotoxicity, myocardial ischemia, chest painCorresponding Author: Anastasios Boutis, 1st Division of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, 54007, Thessaloniki, Greece, tel.: 302310898711, 306937040299, fax:302310845514, e-mail: alboutisotenet.grIntroduction BEP (bleomycin, etoposide, cisplatin) chemotherapeutic regimen represents the regular of care initial line therapy in non-epithelial ovarian tumours1. Cardiovascular toxicity can be a uncommon adverse effect of bleomycin and could be expressed clinically as hypotension, pericarditis, acute substernal chest discomfort, coronary artery illness, myocardial ischemia, myocardial infarction, cerebral vascular accident and Raynaud’s phenomenon2. Case report A 41-year-old woman with sophisticated recurrent ovarian cancer (adult granulosa cell tumor, initial stage pT2b pN1 M0, FIGO IIIC, 4 years prior to) was treated with initially line platinum-based chemotherapy. Pre-treatment cardiovascular danger things included arterial hypertension (effectively controlled with angiotensin II receptor blockers) and obesity (BMI: 40.3 Kgm2). Baseline cardiologic evaluation with ECG and echocardiogram just prior to initiation of chemotherapy was unremarkable. Throughout the initial cycle of therapy and throughout the bleomycin infusion, ch.